Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
AssigneeCellectis
InventorCècile SCHIFFER-MANNIOUI
Life of this patent
Estimating the term…
Abstract
The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a ROR1 monoclonal antibody, conferring specific immunity against ROR1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as breast, colon, lung, and kidney tumors
Claims32
1-54. (canceled)
A ROR1 (NTRKR1) specific chimeric antigen receptor (CAR) having one of the polypeptide structure selected from V3, V5 and V1, said structure comprising an extra cellular ligand binding-domain comprising VH and VL from a monoclonal anti-ROR1 antibody, a hinge, a CD8α transmembrane domain and a cytoplasmic domain including a CD3 zeta signaling domain and a co-stimulatory domain from 4-1BB.
Dependencies are inferred from the claim text.